In Phase 3 Trial, Tumor-Infiltrating Cells Found Highly Effective in Advanced Melanoma

Source: Clinical Oncology News, November 2022

A phase 3 trial comparing tumor-infiltrating cells (TILs) and a checkpoint inhibitor for the treatment of advanced melanoma favored TILs for every end point.

The results included a greater than twofold increase in the proportion of patients achieving a complete response.

“For patients with advanced melanoma, we see a 50% reduction in the chance of progression of the disease or dying from the disease, which is absolutely practice-changing,” reported John Haanen, MD, PhD, a research
READ THE ORIGINAL FULL ARTICLE